Remed Co

Remed Co FCF Margin

The Free Cash Flow Margin of Remed Co (302550.KQ) as of Nov 19, 2026 is 6.23 %. In the previous year, Free Cash Flow Margin was 2.49 % — a change of 150.57% (higher).

FCF Margin

6.23 %

YoY

150.57%

Last updated:

Free Cash Flow Margin of Remed Co is 2025 6.23 % . Free Cash Flow Margin of Remed Co was 2024 2.49 % . It decreases by 150.57% higher compared to the previous year.

The Remed Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-66.52 KRW
Jan 1, 2019
6.54 KRW
Jan 1, 2020
11.49 KRW
Jan 1, 2021
-41.44 KRW
Jan 1, 2022
2.07 KRW
Jan 1, 2023
14.05 KRW
Jan 1, 2024
2.49 KRW
Jan 1, 2025
6.23 KRW
The Remed Co FCF Margin history
YEARFCF MarginYoY
6.23 %+150.57%
2.49 %-82.30%
14.05 %+579.93%
2.07 %-104.99%
-41.44 %-460.69%
11.49 %+75.75%
6.54 %-109.83%
-66.52 %+491.28%
-11.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Free Cash Flow Margin of Remed Co is 6.23 % in 2025.

Free Cash Flow Margin of Remed Co changed from 2.49 % to 6.23 %, representing a 150.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Remed Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Remed Co

All Key Metrics — Remed Co